SPATA31 subfamily A member 7Genealiases: AEP1 · C9orf36 · C9orf36A · FAM75A4 · FAM75A7 · SPATA31A4
Q-omics provides the consensus-scored SPATA31A7 profile across patient tissues and cancer cell-line models. SPATA31A7 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in LIHC. Additionally, SPATA31A7 RNA expression shows 7,033 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight LIHC, and TGCT as cancer lineages where SPATA31A7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SPATA31A7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SPATA31A7 survival associations across molecular data types. SPATA31A7 RNA expression shows survival associations in the most cancer types (14), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SPATA31A7 RNA expression–survival associations across cancer types. High SPATA31A7 expression shows unfavorable associations in LIHC, ESCA, DLBC, UCS and PCPG, but favorable associations in UVM. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for SPATA31A7 RNA expression.
This table shows molecular features associated with SPATA31A7 in patient tissues and cancer cell lines. In patient samples, SPATA31A7 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, SPATA31A7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and UPPER_AERODIGESTIVE_TRACT.
